"Out with the old! Be it the fresh start of a new year or a spring cleaning, consumers are encouraged to take stock of what has surpassed its usefulness. Medicines are no exception.
In 1979, the U.S. Food and Drug Administration (FDA) began "...
Recombinate Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Recombinate Antihemophilic Factor (Recombinant) is a naturally occurring protein in the blood that helps blood to clot used to treat or prevent bleeding episodes in adults and children with hemophilia A. It is also used to control bleeding related to surgery or dentistry in a person with hemophilia, and to prevent joint damage in people age 16 or older with severe hemophilia A and no prior joint damage. It is not for use in people with von Willebrand disease. Common side effects include flushing of the face, headache, nausea, and fast heartbeat and can be lessened by giving this medication more slowly. Burning/redness/irritation at the injection site, fever, and chills may also occur.
Physician supervision of the dosage of Recombinate is required. Recombinate may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Recombinate should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Recombinate Antihemophilic Factor (Recombinant) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Recombinate in Detail - Patient Information: Side Effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; feeling light-headed, fainting; swelling of your face, lips, tongue, or throat.
Stop using recombinant antihemophilic factor and call your doctor at once if you have a serious side effect such as:
- chest pain;
- easy bruising, increased bleeding episodes; or
- bleeding from a wound or where the medicine was injected.
Less serious side effects may include:
- sore throat, cough, runny nose;
- fever or chills;
- mild nausea, vomiting;
- unusual or unpleasant taste in your mouth;
- skin itching or rash;
- warmth, redness, itching, or tingling under your skin;
- joint pain or swelling;
- headache; or
- swelling, stinging, or irritation where the injection was given.
Read the entire detailed patient monograph for Recombinate (Antihemophilic Factor (Recombinant))
What is Patient Information Overview?
A concise overview of the drug for the patient or caregiver from First DataBank.
Recombinate Overview - Patient Information: Side Effects
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing, chest discomfort/tightness.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.
In the US -
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Read the entire patient information overview for Recombinate (Antihemophilic Factor (Recombinant))
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Recombinate FDA Prescribing Information: Side Effects
During the clinical studies conducted in the previously treated patient group, there were 13 infusion related minor adverse reactions reported out of 10,446 infusions (0.12%).
One patient experienced flushing and nausea during his first infusion which abated on decreasing the infusion rate. A second patient experienced mild fatigue during and following one infusion and a third patient had a series of eleven nose bleeds with a periodicity associated with the infusions.
The protein in greatest concentration in RECOMBINATE (antihemophilic factor (recombinant)) rAHF is Albumin (Human). Reactions associated with intravenous administration of albumin are extremely rare, although nausea, fever, chills or urticaria have been reported. Other allergic reactions could theoretically be encountered in the use of this Antihemophilic Factor preparation. See Information for Patients.
Read the entire FDA prescribing information for Recombinate (Antihemophilic Factor (Recombinant))
Additional Recombinate Information
Report Problems to the Food and Drug Administration
Find out what women really need.